TransMedics Group (TMDX) Reports Third-Quarter 2026 Earnings, Raises Revenue Outlook

Image source: The Motley Fool.

Third-Quarter 2026 Highlights

TransMedics Group reported a record third quarter in 2026, posting total revenue of approximately $203 million, up 41% from the prior year. The company said the growth was driven by increased liver and heart volumes through its National OCS Program, as well as higher transplant product and service revenue.

Product revenue reached $113.4 million, up 29%, while service revenue totaled $89.6 million, up 60%. Transplant logistics revenue was $41 million, up 50%, reflecting the company’s continued scaling of its owned aviation fleet. TransMedics ended the quarter with $493 million in cash and cash equivalents.

Financial and Operational Takeaways

TransMedics reported net income of $17.1 million, or $0.46 per diluted share, and adjusted net income of $18.9 million, or $0.51 per diluted share. Product gross margin was 79.2%, up 50 basis points, while service gross margin improved 440 basis points to 32.2%. The company said the PAD Aviation acquisition weighed on consolidated gross margin by 260 basis points.

The company raised its full-year 2026 revenue guidance to $764 million to $774 million from a prior range of $737 million to $757 million. It continues to expect adjusted operating margin of 12.5% to 14%.

Clinical and Strategic Progress

TransMedics said the ENHANCE Heart Part A trial enrolled 175 patients, and the FDA approved a continued access protocol covering 90 additional patients. The company also received FDA approval for protocol amendments for the ENHANCE Heart Part B and DENOVO Lung trials that included the TransMedics CHOPS as a control arm. Development of the OCS Kidney remains on schedule for first human clinical experience in the second half of 2027.

The company is preparing to launch OCS services in Italy, the Netherlands, and Belgium in the first half of 2027 and recently won a European transplant logistics tender in Italy’s Emilia-Romagna region.

Summary

TransMedics reported record revenue and case volumes in the third quarter of 2026, overcoming a 6% decline in U.S. disease donor organ volume. Management raised full-year revenue guidance and cited margin expansion in product and service segments, despite margin dilution from PAD Aviation. The company said its strategy remains focused on expanding its clinical trial pipeline and building a vertically integrated transplant logistics network in the United States and Europe.

Risks

Management noted that October was “clearly a soft month,” citing initial fourth-quarter flight trends that were down compared with prior periods.

Industry Glossary

• OCS (Organ Care System): A portable technology platform that recreates near-physiological conditions to preserve and monitor donor organs outside the body.
• NOP (National OCS Program): TransMedics’ clinical service offering in which its personnel manage the preservation and transport of donor organs.
• DBD (Donation after Brain Death): Organ donation following the irreversible cessation of all functions of the brain.
• DCD (Donation after Circulatory Death): Organ donation following the permanent cessation of circulatory and respiratory function.
• CHOPS (Controlled Hypothermic Organ Preservation System): A cold preservation technology used as a control arm in current clinical trials.
• IDE (Investigational Device Exemption): An FDA regulatory status that allows an unapproved device to be used in a clinical study.
• OPO (Organ Procurement Organization): A non-profit organization responsible for the evaluation and procurement of deceased-donor organs for transplant.
• DSA (Donor Service Area): The designated geographic region assigned to a specific Organ Procurement Organization.
• PMA (Post-Market Approval): The FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices.

Source link